- TRADE NAME: Mekinist (Novartis)
- INDICATIONS: Melanoma (unresectable or metastatic) in patients with BRAF V600E or V600K mutations
- CLASS: MEK inhibitor (mitogen-activated protein kinase (MEK1 and MEK2) inhibitor)
- HALF-LIFE: 4–5 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
MEK inhibitor (mitogen-activated protein kinase (MEK1 and MEK2) inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dabrafenib with trametinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/22/2025
